Loading...
Radiogenomics in the era of advanced radiotherapy
Brothwell, M West, Catharine ML Dunning, A Burnet, Neil G Barnett, G
Brothwell, M
West, Catharine ML
Dunning, A
Burnet, Neil G
Barnett, G
Citations
Altmetric:
Abstract
Most radiogenomics studies investigate how genetic variation can help to explain the differences in early and late radiotherapy toxicity between individuals. The field of radiogenomics in photon beam therapy has grown rapidly in recent years, carving out a unique translational discipline, which has progressed from candidate gene studies to larger scale genome-wide association studies, meta-analyses and now prospective validation studies. Genotyping is increasingly sophisticated and affordable, and whole-genome sequencing may soon become readily available as a diagnostic tool in the clinic. The ultimate aim of radiogenomics research is to tailor treatment to the individual with a test based on a combination of treatment, clinical and genetic factors. This personalisation would allow the greatest tumour control while minimising acute and long-term toxicity. Here we discuss the evolution of the field of radiogenomics with reference to the most recent developments and challenges.
Authors
Brothwell, M
West, Catharine ML
Dunning, A
Burnet, Neil G
Barnett, G
West, Catharine ML
Dunning, A
Burnet, Neil G
Barnett, G
Affiliation
Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
Description
Date
2019
Publisher
Collections
Keywords
Type
Article
Citation
Brothwell MRS, West CM, Dunning AM, Burnet NG, Barnett GC. Radiogenomics in the era of advanced radiotherapy. Clin Oncol. 2019 May;31(5):319-25.